| 10.14 0.27 (2.74%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.11  |
1-year : | 20.95 |
| Resists | First : | 14.65 |
Second : | 17.94 |
| Pivot price | 10.91 |
|||
| Supports | First : | 9.34 |
Second : | 7.77 |
| MAs | MA(5) : | 10.14 |
MA(20) : | 11.66 |
| MA(100) : | 11.94 |
MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 10.9 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 19.57 | Low : | 4.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AARD ] has closed above bottom band by 24.5%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.24 - 10.31 | 10.31 - 10.37 |
| Low: | 9.21 - 9.29 | 9.29 - 9.34 |
| Close: | 10.04 - 10.16 | 10.16 - 10.25 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Wed, 05 Nov 2025
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Target Price at $31.43 - Defense World
Tue, 04 Nov 2025
Aardvark (NASDAQ: AARD) to Start Phase 2 POWER Trial in 2025 for ARD-201 in obesity - Stock Titan
Mon, 06 Oct 2025
Insiders Rewarded With US$275k Addition To Investment As Aardvark Therapeutics Stock Hits US$349m - simplywall.st
Fri, 12 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD - Investing.com Nigeria
Fri, 12 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD - Investing.com
Thu, 14 Aug 2025
Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) stock price dropped 11% last week; individual investors would not be happy - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 50.6 (%) |
| Shares Short | 560 (K) |
| Shares Short P.Month | 404 (K) |
| EPS | -1.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -33.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -6 |
| PEG Ratio | 0 |
| Price to Book value | 1.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|